Skip to content
ClinCalc Pro
Menu
Amphenicol — Meningitis (Alternative) / Topical Eye Infections Pregnancy: Contraindicated in pregnancy and whilst breastfeeding (UK SPC).

Chloramphenicol

Brand names: Kemicetine (systemic), Chloramphenicol eye drops/ointment

Chloramphenicol is a broad-spectrum amphenicol antibiotic. Systemic use is now reserved for serious infections where safer alternatives are unsuitable, while topical eye and ear preparations remain in common use for superficial bacterial infection.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 1 g (equivalent of chloramphenicol)
Route: intravenous injection or infusion, or intramuscular injection
Frequency: every 6-8 hours
Dose and concentration depend on severity of infection. Adults: equivalent of 1 g every 6-8 hours. Elderly: usual adult dosage subject to normal hepatic and renal function. In exceptional cases (septicaemia or meningitis) schedules up to 100 mg/kg/day may be prescribed but should be decreased as soon as clinically indicated. Continue treatment after temperature returns to normal for 4 days in rickettsial diseases and 8-10 days in typhoid fever. Best given IV (10% / 100 mg/mL solution over at least 1 minute, or by slow infusion); IM absorption slow and unpredictable. Reserve for serious infections where less toxic antibiotics are ineffective or contraindicated; monitor serum levels and haematology.

Paediatric dose

Dose: 50 mg/kg
Route: intravenous injection or infusion, or intramuscular injection
Frequency: daily in divided doses every 6 hours
Max: 50 mg/kg/day (this dose should not be exceeded; up to 100 mg/kg/day only in exceptional cases such as septicaemia or meningitis, decreased as soon as clinically indicated)
Children: equivalent of 50 mg/kg chloramphenicol per day in divided doses every 6 hours; observe carefully for signs of toxicity. Neonates and premature infants: total 25 mg/kg/day in 4 equal doses at 6-hour intervals; risk of neonatal Grey syndrome. Verify against a children's formulary.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

Children: equivalent of 50 mg/kg chloramphenicol per day in divided doses every 6 hours; observe carefully for signs of toxicity. Neonates and premature infants: total 25 mg/kg/day in 4 equal doses at 6-hour intervals; risk of neonatal Grey syndrome. Verify against a children's formulary.

Verify in a children's formulary

Contraindications

  • Previous history of sensitivity and/or toxic reaction to chloramphenicol
  • Pregnancy and breast-feeding
  • Trivial infections, or where not indicated (e.g. colds, influenza, throat infections), or as prophylaxis

Side effects

  • Bone marrow depression / blood dyscrasias (aplastic anaemia, agranulocytosis, pancytopenia, thrombocytopenic purpura)
  • Neonatal Grey syndrome
  • Peripheral neuritis; optic neuritis; blurred/transient loss of vision
  • Vomiting, diarrhoea, nausea, dry mouth
  • Fungal superinfection; urticaria

Interactions

  • Other drugs that may cause bone marrow depression — concurrent therapy should be avoided
  • Monitor serum levels particularly in neonates/premature infants, elderly, renal or hepatic disease, and with other interacting drugs

Clinical monograph

How it works

It binds reversibly to the bacterial 50S ribosomal subunit and inhibits peptidyl transferase, thereby blocking protein synthesis; it is usually bacteriostatic.

Prescribing in practice

  • Systemic chloramphenicol can cause dose-independent, irreversible aplastic anaemia and dose-related reversible bone-marrow suppression, so systemic courses must be kept as short as possible with close haematological supervision.
  • Avoid in neonates where it can precipitate grey baby syndrome from impaired conjugation and reduced clearance.
  • It inhibits hepatic cytochrome P450 enzymes and can raise levels of warfarin, phenytoin and sulfonylureas.

Monitoring

Monitor the full blood count regularly during systemic therapy, and consider plasma-concentration monitoring in neonates, infants and patients with hepatic impairment.

Counselling the patient

  • Report any unexplained fever, sore throat, bruising or bleeding promptly as these may signal blood disorders.
  • Complete the full course even once you feel better.

Evidence & guidelines

Chloramphenicol is a long-established agent whose haematological toxicity is documented in MHRA safety guidance and standard prescribing references.

Reference: PHE Meningitis Antibiotic Guidelines; NICE NG 41 Meningitis; WHO Essential Medicines List 2023; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.